• 1
    Laine L. GI risk and risk factors of NSAIDs. J Cardiovasc Pharmacol 2006; 47(Suppl 1): S606.
  • 2
    Rahme E, Joseph L, Kong SX, et al. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population. Arthritis Rheum 2000; 43: 91724.
  • 3
    Smalley WE, Griffin MR, Fought RL, et al. Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs. J Gen Intern Med 1996; 11: 4619.
  • 4
    Bloom BS. Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. Am J Med 1986; 84(Suppl 2A): 204.
  • 5
    Wilcox CM, Allison J, Benzuly K, et al. Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroenterol Hepatol 2006; 4: 10829.
  • 6
    Rostom A, Moayyedi P, Hunt R. Canadian Association of Gastroenterology Consensus Group Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther 2009; 29: 48196.
  • 7
    Lanza FL, Chan FKL, Quigley EMM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104: 72838.
  • 8
    Abraham NS, El-Serag HB, Johnson ML, et al. National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterology 2005; 129: 11718.
  • 9
    Laine L, Connors L, Griffin MR, et al. Prescription rates of protective co-therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines. Aliment Pharmacol Ther 2009; 30: 76774.
  • 10
    Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Int Med 1995; 123: 2419.
  • 11
    Laine L, Bombardier C, Hawkey CJ, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002; 123: 100612.
  • 12
    Hawkey CJ, Weinstein WM, Smalley W, et al. Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study. Gastroenterology 2007; 133: 5764.
  • 13
    Cannon CP, Curtis SP, Bolognese JA, et al. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) Study Program: cardiovascular outcomes with etoricoxib vs diclofenac in patients with osteoarthritis and rheumatoid arthritis. Am Heart J 2006; 152: 23745.
  • 14
    Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006; 368: 177181.
  • 15
    Laine L, Curtis SP, Cryer B, et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007; 369: 46573.
  • 16
    Rostom A, Muir K, Dube C, et al. The gastrointestinal toxicity of COX-2 inhibitors: a Cochrane Collaboration Systematic Review. Clin Gastroenterol Hepatol 2007; 5: 81828.
  • 17
    Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987; 28: 52732.
  • 18
    Holvoet J, Terriere L, Van Hee W, et al. Relation of upper gastrointestinal bleeding to non-steroidal anti-inflammatory drugs and aspirin: a case control study. Gut 1991; 32: 7304.
  • 19
    Hansen JM, Hallas J, Lauritsen JM, et al. Non-steroidal anti-inflammatory drugs and complications: a risk factor analysis for clinical decision-making. Scand J Gastroenterol 1996; 31: 12630.
  • 20
    Singh G, Ramey DR, Morfeld D, et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 1996; 156: 15306.
  • 21
    Rockall TA, Logan RF, Devlin HB, et al. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996; 38: 31621.
  • 22
    FDA Arthritis Advisory Committee Meeting. February 7, 2001. Available at:
  • 23
    Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 15208.
  • 24
    Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364: 66574.
  • 25
    Van Soest EM, Sturkenboom MCJM, Dieleman JP, Verhamme KMC, Siersema PD, Kuipers EJ. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther 2007; 26: 26575.
  • 26
    Larkai EN, Smith JL, Lidsky MD, et al. Dyspepsia in NSAID users: the size of the problem. J Clin Gastroenterol 1989; 11: 15862.